Meng Tingting, a trainee reporter of this newspaper
On March 20, Weixinkang issued an announcement that Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the "Drug Registration Approval Document" for a variety of trace element injections approved and issued by the State Drug Administration.
According to the announcement, the drug application for registration approval of the drug name is "a variety of trace element injection", the specification is 40ml, and it is valid until March 16, 2025. A variety of trace element injections are trace element supplements containing 10 trace elements and are suitable for adult patients who require parenteral nutrition.
According to Wei Xinkang, in November 2013, Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary, submitted a drug registration application to the Food and Drug Administration of Inner Mongolia Autonomous Region with the drug name "Mixed Trace Element Injection (10)" and was accepted, and at the same time, the relevant raw materials such as gluconolactone and manganese gluconate were declared, and the relevant raw materials and excipients have passed the technical review, and the filing status is: A. The company said that at present, the research and development costs of a variety of trace element injection projects have invested about 25.7103 million yuan.
It is reported that the original research product of a variety of trace element injections is DECAN® of the French LABELATOIREAGUETTANT company, which is currently listed and sold in many foreign countries. The product was approved for import into China in December 2011, and the commodity name is "Laiwei". After query and search, the only domestic approved manufacturer of a variety of trace element injections is the French LABELATOIREAGUETTANT company. At the same time, as of March 20, 2020, no other manufacturers in China have declared a variety of trace element injections. In addition, there are 4 manufacturers of multiple trace element injection (II.) of the same kind for adults to supplement trace elements.
Weixinkang said that the company has begun to prepare for the production of a variety of trace element injections. The "Securities Daily" reporter noted that a variety of trace element injections and a variety of trace elements injections (II.) have been included in the 2019 National Medical Insurance Directory (Class B). According to the statistics of The Intranet, the total national sales of a variety of trace element injections in 2018 were about 232 million yuan, and the total sales of multiple trace elements injections (II.) in 2018 were about 567 million yuan. Industry insiders believe that with the production of a variety of trace element injections, The operating performance of Weixinkang may usher in new growth.
As one of the listed pharmaceutical companies in Tibet, Weixinkang is mainly engaged in the research and development, production and sales of chemical preparations and their APIs. The company's product line mainly revolves around intravenous vitamin supplements, intravenous electrolyte supplements, intravenous iron supplements and other fields, the main products are 12 kinds of multivitamins for injection, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc.
(Edited by Sun Qian)
This article originated from securities daily